Lag-3 Research Operative, page-19

One of the key points from your Labcorp link -

“Advanced our leadership position in oncology: Expanded Labcorp’s leadership through strategic partnerships in oncology testing, major customer wins in late-stage clinical trials and the addition of leaders in the field to further build our Enterprise Oncology team.”

We must be one of the “leaders” in the field.
The Labcorp Immutep agreement is a “license and collaboration agreement” involving payments to Immutep on certain milestones being reached and according to how many drugs(or new treatable indications identified for existing drugs) are bought to market via the Labcorp/Immutep technology.

Interestingly, the collaboration doesn’t involve any of Immutep’s in-house programs in oncology or autoimmune.

Quote-“ Significantly, it allows the company to enter the immuno-oncology diagnostics field”

So incidentally the relationship with Labcorp may help identify indications and drugs that Efti can work with but I don’t think that is where the value is in the collaboration.

What I don’t think is appreciated here is that Labcorp and Immutep are jointly developing a diagnostic tool. This is quite a new direction for Immutep. And it also shows the very high value of our intellectual property in general. Labcorp isn’t small beer.

On the chance this jointly developed technology becomes an industry standard tool Immutep may get quite a revenue stream. And I would assume a lot more will come from this relationship in the fullness of time.

Interested to know what others think.